A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (MAJIC)

NCT05057494 PHASE3 ACTIVE_NOT_RECRUITING

A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Details

Lead sponsor	AstraZeneca
Phase	PHASE3
Status	ACTIVE_NOT_RECRUITING
Enrolment	607
Start date	Mon Sep 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Apr 10 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Interventions

• Acalabrutinib
• Venetoclax
• Obinutuzumab

Countries

France, Hungary, Poland, Australia, United States, Spain, Czechia